Today's Daily Dose brings you news about Xeris Pharma's trial results of ready-to-use (RTU) glucagon for the prevention of exercise-induced hypoglycemia; Merck's Keytruda trial results in patients with extensive-stage small-cell lung cancer; collaboration and license agreement between aTyr Pharma and Kyorin Pharmaceutical.
from RTT - Biotech https://ift.tt/2FpTH3R
via IFTTT
No comments:
Post a Comment